Results 1 to 10 of about 51,821 (267)

Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease [PDF]

Endocrinology and Metabolism, 2022
Background The role of aspirin in primary cardiovascular disease prevention in patients with diabetes remains controversial. However, some studies have suggested beneficial effects of cilostazol on cardiovascular disease in patients with diabetes.
Sangmo Hong, Woo Je Lee, Cheol-Young Park   +2 more
doaj   +1 more source

Aprobation of platelet aggregation inhibitor from Echis multisquamatis snake venom in vitro, in vivo and ex vivo [PDF]

Biotechnologia Acta, 2023
Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients.
Zhelavskyi M. A., Platonov M. O., Kucheryavyi Y. Р., Stohnii Y. M.   +3 more
doaj   +1 more source

The extracellular Ero1α/PDI electron transport system regulates platelet function by increasing glutathione reduction potential

Redox Biology, 2022
Protein disulfide isomerase (PDI), an oxidoreductase, possesses two vicinal cysteines in the -Cys-Gly-His-Cys-motif that either form a disulfide bridge (S–S) or exist in a sulfhydryl form (-SH), forming oxidized or reduced PDI, respectively. PDI has been
Lu Wang, Xi Wang, Xiying Lv, Qiushuo Jin, Hongcai Shang, Chih-chen Wang, Lei Wang   +6 more
doaj   +1 more source

The search of compounds with antiaggregation activity among S-esters of thiosulfonic acids [PDF]

The Ukrainian Biochemical Journal, 2015
According to the current understanding, the hyperactivation of platelets may lead to increased intravascular coagulation and thrombosis. Today a relevant issue is the search for new anti-thrombotic agents that are able to modulate the activity of ...
T. I. Halenova, I. V. Nikolaeva, A. V. Nakonechna, K. B. Bolibrukh, N. Y. Monka, V. I. Lubenets, O. M. Savchuk, V. P. Novikov, L. I. Ostapchenko   +8 more
doaj   +1 more source

Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china

Frontiers in Cardiovascular Medicine, 2022
PurposePrevious trials have demonstrated that ticagrelor was superior to clopidogrel in acute coronary syndrome (ACS) patients. However, several recent studies showed that ticagrelor was associated with a significantly higher risk of bleeding compared ...
Wenxing Peng, Yunnan Zhang, Yunnan Zhang, Yang Lin   +3 more
doaj   +1 more source

Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis

Nature Communications, 2020
Current inhibitors of platelet integrin αIIbβ3 cause excessive bleeding, which limited their clinical use in cardiac patients. Here the authors design pure orthosteric αIIbβ3 inhibitors that prevent platelet aggregation and thrombosis without causing ...
Brian D. Adair, José L. Alonso, Johannes van Agthoven, Vincent Hayes, Hyun Sook Ahn, I-Shing Yu, Shu-Wha Lin, Jian-Ping Xiong, Mortimer Poncz, M. Amin Arnaout   +9 more
doaj   +1 more source

Influence of Platelet Aggregation Modulators on Cyclic AMP Production in Human Thrombocytes

Folia Medica, 2018
Background: Cyclic AMP is a powerful inhibitor of platelet aggregation. In the present study we examined the effect of platelet aggregation modulators on cyclic AMP content in human thrombocytes.
Boyanov Krasimir O., Maneva Ana I.
doaj   +1 more source

Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro

MethodsX, 2019
Platelet aggregometry assays are generally used for the analysis of platelet function but can also be adapted for further research and therapy focused applications.
Alexandros Tsoupras, Ioannis Zabetakis, Ronan Lordan   +2 more
doaj   +1 more source

Comparison of the GPVI inhibitors losartan and honokiol

Platelets, 2020
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen. Honokiol has been reported to bind directly
Marie-Blanche Onselaer, Magdolna Nagy, Chiara Pallini, Jeremy A Pike, Gina Perrella, Lourdes Garcia Quintanilla, Johannes A Eble, Natalie S. Poulter, Johan W.M. Heemskerk, Steve P Watson   +9 more
doaj   +1 more source

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

Frontiers in Cardiovascular Medicine, 2021
Background: Bruton tyrosine kinase inhibitors (BTKi) are used in B-cell malignancies and in development against various autoimmune diseases. Since Btk is also involved in specific pathways of platelet activation, BTKi might be considered to target ...
Rundan Duan, Luise Goldmann, Richard Brandl, Michael Spannagl, Christian Weber, Christian Weber, Christian Weber, Wolfgang Siess, Wolfgang Siess, Philipp von Hundelshausen, Philipp von Hundelshausen   +10 more
doaj   +1 more source